Adcetris Indications/Uses

Adcetris is indicated for the treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL), in combination with doxorubicin, vinblastine, and dacarbazine.
Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT.
Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ HL: following autologous stem cell transplant (ASCT) or; following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
Adcetris is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing Peripheral T-Cell Lymphoma (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin and prednisone.
Adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Adcetris is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.